Edoardo Crimini (Crimini Edoardo)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 7

Top Topics

Endometrial Cancer

Oxide Nanoparticles

Advanced Non Small Cell Lung Cancer

Epidermal Growth Factor Receptor

Top Venues

Expert opinion on investigational drugs

Investigational new drugs

This page only lists publications with an associated author ORCID identifier.

Publications

Edoardo Crimini, Luca Boscolo Bielo, Pier Paolo Berton Giacchetti, Gloria Pellizzari, Gabriele Antonarelli, Beatrice Taurelli Salimbeni, Matteo Repetto, Carmen Belli, Curigliano Giuseppe
Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting. Cancers 16 (2) (2024)
Edoardo Crimini, Luca Boscolo Bielo, Pier Paolo Berton Giacchetti, Gloria Pellizzari, Gabriele Antonarelli, Beatrice Taurelli Salimbeni, Matteo Repetto, Carmen Belli, Curigliano Giuseppe
Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting. Cancers 16 (2) (2024)
Edoardo Crimini, Curigliano Giuseppe
Trastuzumab-Deruxtecan in solid tumors with HER2 alterations: from early phase development to the first agnostic approval of an antibody-drug conjugate. Expert opinion on investigational drugs (2024)
Edoardo Crimini, Luca Boscolo Bielo, Pier Paolo Berton Giacchetti, Gloria Pellizzari, Gabriele Antonarelli, Beatrice Taurelli Salimbeni, Matteo Repetto, Carmen Belli, Curigliano Giuseppe
Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting. Cancers 16 (2) (2024)
Edoardo Crimini, Curigliano Giuseppe
Trastuzumab-deruxtecan in solid tumors with HER2 alterations: from early phase development to the first agnostic approval of an antibody-drug conjugate. Expert opinion on investigational drugs 33 (8) (2024)
Edoardo Crimini, Curigliano Giuseppe
Trastuzumab-deruxtecan in solid tumors with HER2 alterations: from early phase development to the first agnostic approval of an antibody-drug conjugate. Expert opinion on investigational drugs (2024)
Matteo Repetto, Edoardo Crimini, Liliana Ascione, Luca Boscolo Bielo, Carmen Belli, Giuseppe Curigliano
The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046. Investigational new drugs 40 (5) (2022)